Top Markets
#1 EXOD EXOD +22.08%
#2 Derive Derive +21.38%
#3 SSV Network SSV Network +20.00%
#4 Plasma Plasma +19.41%
#5 Unit Plasma Unit Plasma +19.41%
#6 Wrapped XPL Wrapped XPL +19.37%
#7 GALA GALA +19.08%
#8 Arowana Arowana +18.86%
#9 Useless Coin Useless Coin +18.36%
#10 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +18.20%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Sirnaomics Ltd. Sirnaomics Ltd.

Sirnaomics Ltd.

2257
Rank in Stocks #25049
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in... Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Share Price
$0.49443488
Market Cap
$53.84M
Change (1 day)
-0.90%
Change (1 year)
-60.89%
Country
US
Trade Sirnaomics Ltd. (2257)

Category

Healthcare
Operating Margin for Sirnaomics Ltd. (2257)
Operating Margin as of 2026 TTM: 0.00%
According to Sirnaomics Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Sirnaomics Ltd. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.